EcoDrugPlus

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSNGAG00000002741
Gene Symbol: PSMB2
3 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSNGAG00000021971
Gene Symbol: PSMB3
3 Cross references
234 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSNGAG00000014782
Gene Symbol: PSMB4
3 Cross references
213 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSNGAG00000014706
Gene Symbol: PSMB5
3 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSNGAG00000003013
Gene Symbol: PSMB6
3 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSNGAG00000016549
Gene Symbol: PSMB7
3 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSNGAG00000001376
Gene Symbol: PSMB8
3 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSNGAG00000022287
Gene Symbol: PSMB9
3 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSNGAG00000013761
Gene Symbol: PSMC1
3 Cross references
203 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSNGAG00000022781
Gene Symbol: PSMC2
2 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSNGAG00000017843
Gene Symbol: PSMC3
3 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSNGAG00000021618
Gene Symbol: PSMC4
3 Cross references
197 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).